A selective PPAR modulator (SPPARM) is a selective receptor modulator of the peroxisome proliferator-activated receptor (PPAR).[1][2][3] Examples include SPPARMs of the PPARγ, BADGE, EPI-001, INT-131, MK-0533, and S26948.
See also[edit]
References[edit]
- ^ Fruchart, Jean-Charles; Santos, Raul D.; Aguilar-Salinas, Carlos; Aikawa, Masanori; Al Rasadi, Khalid; Amarenco, Pierre; Barter, Philip J.; Ceska, Richard; Corsini, Alberto; Després, Jean-Pierre; Duriez, Patrick; Eckel, Robert H.; Ezhov, Marat V.; Farnier, Michel; Ginsberg, Henry N.; Hermans, Michel P.; Ishibashi, Shun; Karpe, Fredrik; Kodama, Tatsuhiko; Koenig, Wolfgang; Krempf, Michel; Lim, Soo; Lorenzatti, Alberto J.; McPherson, Ruth; Nuñez-Cortes, Jesus Millan; Nordestgaard, Børge G.; Ogawa, Hisao; Packard, Chris J.; Plutzky, Jorge; Ponte-Negretti, Carlos I.; Pradhan, Aruna; Ray, Kausik K.; Reiner, Željko; Ridker, Paul M.; Ruscica, Massimiliano; Sadikot, Shaukat; Shimano, Hitoshi; Sritara, Piyamitr; Stock, Jane K.; Su, Ta-Chen; Susekov, Andrey V.; Tartar, André; Taskinen, Marja-Riitta; Tenenbaum, Alexander; Tokgözoğlu, Lale S.; Tomlinson, Brian; Tybjærg-Hansen, Anne; Valensi, Paul; Vrablík, Michal; Wahli, Walter; Watts, Gerald F.; Yamashita, Shizuya; Yokote, Koutaro; Zambon, Alberto; Libby, Peter (4 June 2019). "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential". Cardiovascular Diabetology. 18 (1): 71. doi:10.1186/s12933-019-0864-7. ISSN 1475-2840. PMC 6549355. PMID 31164165.
- ^ Fruchart, Jean-Charles; Hermans, Michel P.; Fruchart-Najib, Jamila; Kodama, Tatsuhiko (3 January 2021). "Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?". Current Atherosclerosis Reports. 23 (1): 3. doi:10.1007/s11883-020-00897-x. ISSN 1534-6242. PMC 7779417. PMID 33392801.
- ^ Balint, B. L.; Nagy, L. (March 2006). "Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases". Endocrine, Metabolic & Immune Disorders Drug Targets. 6 (1): 33–43. doi:10.2174/187153006776056620. ISSN 1871-5303. PMID 16611163.